ADAMTS14 and cancer: Subsequent multivariate analysis revealed that lymph node metastasis (95% CI, 1.004-20.42; p = 0.048, HR = 0.048), AJCC advanced cancer stage (95% CI, 1.065–2.183; p = 0.021, HR = 1.5), moderate/poor tumor differentiation (95% CI, 1.191–2.943; p = 0.007, HR = 1.9) and ADAMTS14 negative expression (95% CI, 0.601–1.199; p = 0.0353, HR = 1.2).